An adherence based cost–consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%

By Wong William B.   Patel Vaishali D.   Kowalski Jonathan W.   Schwartz Gail  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1191-1200

Informa Healthcare

Access to resources Recommend Favorite

An update on bimatoprost (Lumigan^®®) in glaucoma therapy

By Noecker Robert J   Earl Melissa L  

Therapy, Vol. 1, Iss. 1, 2004-09 ,pp. : 31-41

Future Medicine

Access to resources Recommend Favorite

The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries

By Holmstrom Stefan   Buchholz Patricia   Walt John   Wickstrøm Jannie   Aagren Mark  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 897-905

Informa Healthcare

Access to resources Recommend Favorite

Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 5, 2015-05 ,pp. : 1384-1394

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comments and reply on The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries

By Soto Javier   Holmstrom Stefan   Buchholz Patricia   Walt John   Wickstrøm Jannie   Aagren Mark  

Current Medical Research and Opinion, Vol. 22, Iss. 10, 2006-10 ,pp. : 1899-1902

Informa Healthcare

Access to resources Recommend Favorite